Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 May;12(5):383-90.
doi: 10.1038/ni.2025.

Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22

Affiliations
Review

Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22

Gregory F Sonnenberg et al. Nat Immunol. 2011 May.

Abstract

The maintenance of barrier function at exposed surfaces of the mammalian body is essential for limiting exposure to environmental stimuli, preventing systemic dissemination of commensal and pathogenic microbes and retaining normal homeostasis of the entire body. Indeed, dysregulated barrier function is associated with many infectious and inflammatory diseases, including psoriasis, influenza, inflammatory bowel disease and human immunodeficiency virus, which collectively afflict millions of people worldwide. Studies have shown that interleukin 22 (IL-22) is expressed at barrier surfaces and that its expression is dysregulated in certain human diseases, which suggests a critical role in the maintenance of normal barrier homeostasis. Consistent with that, studies of mouse model systems have identified a critical role for signaling by IL-22 through its receptor (IL-22R) in the promotion of antimicrobial immunity, inflammation and tissue repair at barrier surfaces. In this review we will discuss how the expression of IL-22 and IL-22R is regulated, the functions of the IL-22-IL-22R pathway in regulating immunity, inflammation and tissue homeostasis, and the therapeutic potential of targeting this pathway in human disease.

PubMed Disclaimer

References

    1. J Clin Invest. 2008 Feb;118(2):534-44 - PubMed
    1. J Immunol. 2002 Jun 1;168(11):5397-402 - PubMed
    1. J Immunol. 2009 Mar 15;182(6):3469-81 - PubMed
    1. Science. 2010 Oct 29;330(6004):665-9 - PubMed
    1. Immunity. 2009 Aug 21;31(2):321-30 - PubMed

Publication types

LinkOut - more resources